UK-453,061

UK-453,061 (lersivirine), a Pfizer drug now being developed by ViiV Healthcare, is a second-generation NNRTI. It does not seem to have a significant effect on CYP3A4 metabolic activity and  appears to be active against the common NNRTI mutations. It is enrolling patients into a phase II study comparing UK-453,061 to efavirenz, both taken with Truvada.1

References

  1. Fatkenheuer G et al. Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV-infected patients. Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, abstract WESS202, 2007
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.